Abstract
Lacidipine (LCDP) is a dihydropyridine derivative categorized as an Anti-hypertensive Ca+2 channel blocker belonging to BCS class IV drug with low solubility and low permeability which presents a challenge to the formulation scientists. The development of a solid dispersion by solvent evaporation is a practically viable method to enhance dissolution of LCDP from oral dosage form. Solvent evaporation by Fluidized Bed Process (FBP) was the method of choice for SD as it improves wettability with simultaneous increase in porosity of granules resulting enhanced surface area producing higher dissolution rate and bioavailability of poorly water-soluble drug. Thus, the main object of the present invention is to provide stable pharmaceutical dosage form of LCDP with desired dissolution rate i.e. at least 80% drug release within 45 minutes, without use of disintegrant(s) and/or surfactant(s) or without micronization of the active ingredient per se. One more object of this invention is to provide a sophisticated robust process for the preparation of said pharmaceutical dosage form by Quality by Design (QbD) concept focusing on thorough understanding of the product and process by which it is developed and manufactured along with a knowledge of the risks involved in manufacturing by IRMA & FMEA study of the product with process and how best to mitigate those risks by developing design space with DoE & MVDA with outlined control strategy.
References
Micheli D,Collodel A, Semeraro C, Gaviraghi G et al; “Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies”, Journal of Cardiovascular Pharmacology, 1990, 15(4): 666-675
Pellegatti M, Grossi P, Ayrton J, Evans GL, Harker AJ. “Absorption, distribution and excretion of lacidipine, a dihydropyridine calcium antagonist, in rat and dog”, Xenobiotica, 1990 ;20(8):765-77.
Gannu R, Palem CR et al., “Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: Formulation optimization, ex vivo and in vivo characterization”, International Journal of Pharmaceutics, Volume 388, Issues 1-2, 30 March 2010, Pages 231-241
Martinez MN, Amidon GL, A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals, Pharmacokinetics and pharmacodynamics, Journal of Clinical Pharmacology, 2002;42:620-643
WIPO Patent publication no: WO1995/08987
Venkataraman S, Kharkar M R et al; Lacidipine Particles, WIPO Patent publication no: WO/2006/11330. http://www.wipo.int/patentscope/search/en/WO2006113309
Sharma A, Jain CP, “Solid dispersion: A promising technique to enhance solubility of poorly water soluble drug”,International Journal of Drug Delivery 3, 2011, 149-170
Shinde AJ, “Solubilization of Poorly Soluble Drugs: A Review”, from Pharmainfo.net available online at: http://www.pharmainfo.net/reviews/solubilization-poorly-soluble-drugs-review
Ghaste R, “Solid Dispersions : An Overview”, from Pharmainfo.net available online at: http://www.pharmainfo.net/reviews/solid-dispersions-overview
PatidarKalpana et al.,Solid Dispersion: Approaches, Technology involved, Unmet need & Challenges, Drug Invention Today 2010, 2(7),349-357
Kushawaha A, “Solid Dispersion a Promising Novel Approach for Improving the Solubility of Poorly Soluble Drugs”, PHARMATUTOR-ART-1085, from Pharmatutor.com, online available at:http://www.pharmatutor.org/articles/solid-dispersion%E2%80%93a-promising-novel-approach-for-improving-the-solubility-of-poorly-soluble-drugs
Arunachalam A, Karthikeyan M, Konam K, Pottabathula HP, Sethuraman S, Ashutoshkumar S, “Solid Dispersions: A Review”, Current PharmaResearch, Vol. 1, Issue 1, 2010: available online at: http://www.cpronline.in/PDF/82-90.pdf
Betageri G.V. , Makarla1 K.R., Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques”, International Journal of Pharmaceutics, Volume 126, Issues 1-2, 1995, 155-160
Damian F, Blaton N, Kinget R and Mooter G Van den. “Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire 44/14 and PVP K3”. International Journal of Pharmaceutics , 244, 2002, 87- 98.
ICH (International Conference on Harmonization) – Q 3C (R4) Guideline for“Impurities: Residual Solvents”, Reference no: CPMP/ICH/283/95, July 2010, online available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002674. df
ICH (International Conference on Harmonization) – Q 3C (R5) “Impurities: Guidelines for Residual Solvents”, Reference no: CPMP/ICH/283/95, March 2011, online available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/03/WC500104258.p f
“Type and Mechanism of Tablet Disintegrant” from Vinensia.com, online available at : http://formulation.vinensia.com/2010/08/type-and-mechanism-of-tablet.html
ICH (International Conference on Harmonization) – Q 8 (R2) Guideline for “Pharmaceutical development”, Reference no: CHMP/ICH/167068/04, November 2005, online available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002872.pdf
ICH (International Conference on Harmonization) - Q 9Guideline for “Quality risk management”, Reference no: INS/GMP/79766/2011, February 2011, online available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002873.pdfICH (International Conference on Harmonization) - Q 10 Note for guidance on “Pharmaceutical quality system”, Reference no: INS/GMP/79818/2011, February 2011, online available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002871.pdf
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array